NervGen Pharma Announces Leadership Transition
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2022) - NervGen Pharma Corp. (OTCQX: NGENF) (TSXV: NGEN), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced today that the Board of Directors and Paul Brennan have mutually agreed that Mr. Brennan will step down as
2022-09-22 7:21 PM EDT
NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, is pleased to announce the appointment of Matvey Lukashev, PhD, as the Company's Vice President, Research and Preclinical Development. "We are delighted to welcome Dr. Lukashev to our team," stated Paul Brennan, President & CEO...
2022-09-12 8:30 AM EDT
NervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will present a poster at the upcoming Military Health System Research Symposium (MHSRS) on September 12-15, 2022 and will also present an oral presentation at the 61st International Spinal Cord Society (ISCoS) Annual Scientific...
2022-09-08 8:30 AM EDT
NervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, today reported its fina
2022-08-10 8:30 AM EDT
NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International Conference
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Phase 1b/2a Alzheimer's disease clinical trial at the 2022 Alzheimer's Association International Conference (AAIC) on August 3, 2022. NervGen's Chief Medical Officer, Dr. Daniel Mikol, will present a poster...
2022-08-02 8:30 AM EDT
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 150,000 incentive stock options to a director exercisable at a price of $1.99 per share for a period of five years and that vest equally every three months over a one-year period. All...
2022-07-15 8:49 AM EDT
NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its previously announced non-brokered private placement (the "Private Placement") of 10,150,000 units of the Company at a price of US$1.50 per unit (the "Unit Price"), for aggregate gross proceeds to...
2022-07-14 9:05 AM EDT
NervGen Pharma Provides Update on Closing of Private Placement
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has received conditional approval from the TSX Venture Exchange ("TSXV") for its previously announced US$15,225,000 non-brokered private placement (the "Private Placement"). One of the participants in the Private...
2022-07-11 8:30 AM EDT
NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, is pleased to announce that it has entered into binding subscription agreements for a non-brokered private placement (the "Private Placement") of 10,150,000 units of the Company at a price of US$1.50 per unit (the "Unit Price"),...
2022-06-30 8:30 AM EDT
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock options to a director exercisable at a price of $2.08 per share for a period of five years with vesting that is either time or performance based. All options have...
2022-05-31 5:32 PM EDT
NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will host a 1-hour panel discussion on May 18 at the 2022 American Spinal Cord Injury Ass
2022-05-16 8:30 AM EDT
NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, today announced it has received approval from the Safety Review Committee to ad
2022-05-12 8:30 AM EDT
NervGen Pharma Appoints Craig Thompson to the Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company developing a first-in-class neuroreparative drug to treat nervous system damage, today announced the appointment of Craig Thompson to NervGen's Board of Directors. NervGen's Executive Chairman, Bill Radvak, stated, "We are very pleased to have Craig Thompson join our Board of Directors
2022-04-13 8:30 AM EDT
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - April 6, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 376,000 incentive stock options to Employees and Officers exercisable at a price of $2.06 per share for a period of 10 years and that vest equally every six months over a two-year period....
2022-04-06 5:45 PM EDT
NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will provide an update on its Phase 1 program with NVG-291 in healthy volunteers at the 2022 American Acad
2022-03-31 8:30 AM EDT
NervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim Group
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the 2022 Virtual Growth Conference presented by Maxim Group, being held virtually on March 28-30, 2022. Paul Brennan, NervGen's President and CEO, will provide an overview of the Company's operations and the...
2022-03-23 8:30 AM EDT
NervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions fo
2022-03-15 8:30 AM EDT
NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Study
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2021. "We have continued to make important progress in our Phase 1 clinical trial with NVG-291 in the fourth quarter of 2021 and early 2022,"...
2022-02-28 8:30 AM EST
NervGen Pharma Applauds President Biden Signing Defense Bill
Cincinnati, Ohio--(Newsfile Corp. - January 4, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) through its subsidiary, NervGen US Inc., ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds President Biden for signing the Fiscal Year 2022 National Defense Authorization Act (FY22 NDAA) into law on December 27th, 2021. The Senate report accompanying the legislation included specific encouragement...
2022-01-04 5:00 PM EST
NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments that repair nervous system damage, is pleased to announce it has received ethics board approval from Bellberry Limited's Human Research Eth
2021-12-22 8:30 AM EST